BRPI0412986A - composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado - Google Patents

composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado

Info

Publication number
BRPI0412986A
BRPI0412986A BRPI0412986-5A BRPI0412986A BRPI0412986A BR PI0412986 A BRPI0412986 A BR PI0412986A BR PI0412986 A BRPI0412986 A BR PI0412986A BR PI0412986 A BRPI0412986 A BR PI0412986A
Authority
BR
Brazil
Prior art keywords
compound
preparing
angiogenesis
disease
kit
Prior art date
Application number
BRPI0412986-5A
Other languages
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Publication of BRPI0412986A publication Critical patent/BRPI0412986A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, MéTODO PARA O DIAGNóSTICO OU FORMAçãO DE IMAGEM IN VIVO DE UMA DOENçA OU CONDIçãO ASSOCIADAS COM A ANGIOGêNESE, FORMULAçãO RADIOFARMACêUTICA, MéTODO PARA A PREPARAçãO DE UM COMPOSTO, E, KIT PARA A PREPARAçãO DE UM PEPTìDEO RADIOFLUORADO". A invenção diz respeito a compostos de fórmula (I): e seu uso como vetores de alvejamento que se ligam aos receptores associados com a angiogênese. Tais compostos podem, assim, ser usados para o diagnóstico ou a terapia de, por exemplo, doenças malignas, doenças do coração, endometriose, doenças relacionadas à inflamação, artrite reumatóide e sarcoma de Kaposi.
BRPI0412986-5A 2003-07-30 2004-07-21 composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado BRPI0412986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317815.9A GB0317815D0 (en) 2003-07-30 2003-07-30 Imaging agents
PCT/GB2004/003150 WO2005012335A1 (en) 2003-07-30 2004-07-21 Imaging agents

Publications (1)

Publication Number Publication Date
BRPI0412986A true BRPI0412986A (pt) 2006-10-03

Family

ID=27799463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412986-5A BRPI0412986A (pt) 2003-07-30 2004-07-21 composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado

Country Status (23)

Country Link
US (2) US7410943B2 (pt)
EP (1) EP1648925B1 (pt)
JP (1) JP4625002B2 (pt)
KR (1) KR101153529B1 (pt)
CN (1) CN1829735B (pt)
AT (1) ATE442379T1 (pt)
BR (1) BRPI0412986A (pt)
CA (1) CA2533321C (pt)
CY (1) CY1109522T1 (pt)
DE (1) DE602004023092D1 (pt)
DK (1) DK1648925T3 (pt)
ES (1) ES2332722T3 (pt)
GB (1) GB0317815D0 (pt)
HU (1) HUP0600230A3 (pt)
IL (1) IL173029A0 (pt)
MX (1) MXPA06001090A (pt)
NO (1) NO20060825L (pt)
NZ (1) NZ544583A (pt)
PL (2) PL1648925T3 (pt)
PT (1) PT1648925E (pt)
RU (2) RU2355702C2 (pt)
SI (1) SI1648925T1 (pt)
WO (1) WO2005012335A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2005058367A2 (en) 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
DE602005025911D1 (de) 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007122488A2 (en) * 2006-04-20 2007-11-01 Hammersmith Imanet Limited Radiofluorinated compounds and their preparation
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
RU2498798C2 (ru) * 2008-01-09 2013-11-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Ингибиторы карбоангидразы iх
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのｐｅｇ−６成分の合成
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
WO2011084763A1 (en) 2009-12-21 2011-07-14 Ge Healthcare Limited Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f ion
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
PE20140636A1 (es) 2010-09-30 2014-06-18 Astrazeneca Ab Conjugado de naloxol-peg cristalino
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201511036D0 (en) 2015-06-23 2015-08-05 Guy S And St Thomas Hospital Nhs Foundation Trust Imaging method
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230525T2 (de) 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
AU2001288847A1 (en) * 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
IL141276A0 (en) * 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal

Also Published As

Publication number Publication date
CA2533321C (en) 2012-09-18
HUP0600230A2 (en) 2007-01-29
JP2007523880A (ja) 2007-08-23
US20060193773A1 (en) 2006-08-31
KR101153529B1 (ko) 2012-06-11
CY1109522T1 (el) 2014-08-13
IL173029A0 (en) 2006-06-11
RU2006102324A (ru) 2007-09-20
PT1648925E (pt) 2009-12-10
KR20060090795A (ko) 2006-08-16
SI1648925T1 (sl) 2010-01-29
HK1097278A1 (en) 2007-06-22
US7410943B2 (en) 2008-08-12
PL1648925T3 (pl) 2010-02-26
GB0317815D0 (en) 2003-09-03
US7811551B2 (en) 2010-10-12
RU2009105640A (ru) 2010-08-27
RU2355702C2 (ru) 2009-05-20
MXPA06001090A (es) 2006-04-24
CN1829735A (zh) 2006-09-06
PL379705A1 (pl) 2006-11-13
ES2332722T3 (es) 2010-02-11
NZ544583A (en) 2009-12-24
EP1648925B1 (en) 2009-09-09
CN1829735B (zh) 2010-05-26
EP1648925A1 (en) 2006-04-26
JP4625002B2 (ja) 2011-02-02
NO20060825L (no) 2006-03-29
PL210122B1 (pl) 2011-12-30
US20080267881A1 (en) 2008-10-30
ATE442379T1 (de) 2009-09-15
CA2533321A1 (en) 2005-02-10
DK1648925T3 (da) 2010-01-04
DE602004023092D1 (de) 2009-10-22
WO2005012335A1 (en) 2005-02-10
HUP0600230A3 (en) 2009-09-28

Similar Documents

Publication Publication Date Title
BRPI0412986A (pt) composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado
Baratto et al. Prostate cancer theranostics targeting gastrin-releasing peptide receptors
BRPI0210886B8 (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
Diem et al. The effect of a nano-filled resin coating on the 3-year clinical performance of a conventional high-viscosity glass-ionomer cement
Kuil et al. Imaging agents for the chemokine receptor 4 (CXCR4)
Wild et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
NO20004795D0 (no) Peptidbaserte forbindelser
Yang et al. 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging
BR0013171A (pt) Agentes multimericos para formação de imagem de objetivação através de ligação multi-local
Oliveira et al. Biomedical applications of radioiodinated peptides
Bandara et al. Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist,[RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer
Reddiar et al. A biodistribution study of the radiolabeled Kv1. 3-blocking peptide DOTA-HsTX1 [R14A] demonstrates brain uptake in a mouse model of neuroinflammation
EP4282490B1 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
EA202091767A1 (ru) Новый способ получения визуализирующего соединения
BR0316193A (pt) Composto, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
RU2013113677A (ru) Визуализирующие апоптоз агенты на основе лантибиотических пептидов
MX2009006028A (es) Compuestos basados en peptido radiomarcado y usos de los mismos.
Ding et al. A human GRPr‐transfected Ace‐1 canine prostate cancer model in mice
ATE355304T1 (de) Radiomarkierte vip-analoge zur diagnose und therapie
Q Shah et al. Synthesis of 99mTc-Rifabutin: a potential tuberculosis radiodiagnostic agent
Liu et al. A Uniquely Modified DKL-based Peptide Probe for Positron Emission Tomography Imaging
Romantini Bivalent GPCR Ligands with a Rigid Oligoproline Backbone: Evaluation as Radiopharmaceuticals and Influence on Receptor Dimerization and Receptor Signalling
Jaskula-Sztul et al. 2018 Synaptic vesicle 2 receptors as a novel targets forneuroendocrine cancer therapy
CL2025000435A1 (es) Formulaciones para radioterapia y toma de imágenes diagnósticas y su uso en el tratamiento, el diagnóstico y la toma de imágenes de enfermedades.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GE HEALTHCARE AS (NO)

Free format text: ALTERADO DE: AMERSHAM HEALTH AS

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014.

B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 47/60 (2017.01), A61K 47